

Cover Story
By Matthew Bin Han Ong
When two women—a patient advocate and a scientist—embarked on a mission to collect “normal” breast tissue for comparative purposes, colleagues in oncology dismissed their idea as wild.
In Brief


Drugs & Targets
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Paychecks stop for HHS workers as shutdown continues















